The podcast discusses the International Council for Harmonisation (ICH) guidelines and their impact on pharmaceutical development. Specifically, the text focuses on the key updates to the ICH guidelines, including Q2(R2)/Q14 for analytical validation, Q5(R2) for viral safety evaluation, and Q9(R1) for quality risk management. The text also examines the ICH's efforts to address emerging technologies in cell and gene therapy and real-world data utilization for safety assessments. Finally, the text discusses the impact of the ICH Biannual Assembly held in June 2024, including progress updates on current guidelines, the introduction of new proposals, and the harmonization of regulatory requirements across different regions.

Support the show

The International Council for Harmonisation (ICH) has updated its guidelines on quality risk management (QRM) with ICH Q9(R1). This update emphasizes a more proactive and structured approach to risk management in the pharmaceutical industry, emphasizing reducing subjectivity and integrating knowledge into risk-based decision-making. The update encourages the use of digital tools and emerging technologies to control risks, and it aims to improve industry consistency and regulatory oversight. The updated guidelines promote a shift to more objective risk assessments, ultimately contributing to a safer and more reliable pharmaceutical industry by reducing quality defects and improving patient outcomes.

Support the show

This Podcast is a guide to authoring a successful CMC Quality Module 3 and Quality Overall Summary (QOS) for a New Drug Application (NDA) submission to the Food and Drug Administration (FDA). Ethan and Desi detail the importance of these documents for demonstrating a product's quality, navigating the regulatory review process, and achieving global market access. They also provides best practices for authoring these documents, common pitfalls to avoid, and strategic advice for optimizing their use. The discussion emphasizes the QOS as a critical component for communicating with regulatory authorities and justifying deviations from standard guidelines, thus streamlining the review process.

Support the show